Blood glycoprotein levels in diabetes mellitus

Jónsson, Ársæll; Wales, J. K.

doi:10.1007/bf00422091

Cited by 58 publications

(31 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A proportion of heparin neutralising activity, however, is contributed by cx-glycoproteins," which are also raised in diabetes. 22 As plasma P-thromboglobulin and platelet factor 4 are released simultaneously from platelets23 the most likely explanation from the present study for a change in heparin neutralising activity during treatment would appear to be a change in ox-glycoprotein components.…”

Section: Discussionmentioning

confidence: 55%

Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics.

Paton¹,

Kernoff²,

Wales³

et al. 1981

BMJ

View full text Add to dashboard Cite

The effect of the sulphonylurea gliclazide on tests of haemostatic function was studied in 14 newly diagnosed non-insulin-dependent diabetics. After two months' treatment with diet alone 11 of the 14 were given gliclazide; the three others remained on dietary treatment. Compared with pretreatment values, significant reductions in platelet retention, factor VIII-related antigen, factor VIII coagulant activity, and plasma heparin neutralising activity accompanied a fall in the plasma glucose concentration due to either diet alone or diet and gliclazide.The beneficial effects of gliclazide on platelet abnormalities seem likely to be due to its hypoglycaemic action rather than to any direct effect on haemostatic function. IntroductionAbnormalities of platelet function and of the coagulation and fibrinolytic systems occur in association with diabetes mellitus.55 The effect of the degree of metabolic control of diabetes on these tests of haemostasis has received little attention, though adrenaline-induced platelet aggregation3 and factor VIII

show abstract

Section: Discussionmentioning

confidence: 55%

Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics.

Paton¹,

Kernoff²,

Wales³

et al. 1981

BMJ

View full text Add to dashboard Cite

show abstract

“…We found that those patients with NIDDM and the cluster of biochemical and clinical features known as syndrome X had the highest concentrations of most acute-phase markers; those with NIDDM but few features of syndrome X had an intermediate-level acute-phase response, but still higher than non-diabetic control subjects. Increases in circulating acute-phase proteins have been recorded before in diabetes [27,28] but the particular associations with NIDDM and syndrome X have not been noted.…”

Section: Discussionmentioning

confidence: 98%

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X

et al. 1997

View full text Add to dashboard Cite

“…Diabetes 49:517-520, 2000 I t has been hypothesized that type 2 diabetes and the insulin resistance syndrome are partly a manifestation of an ongoing acute-phase response (1,2). This hypothesis is based on the findings of increased blood concentrations of markers of the acute-phase response, including C-reactive protein, serum amyloid-A, -1 acid glycoprotein, sialic acid, and cortisol (1)(2)(3)(4).…”

Section: Interleukin-6 Gene Polymorphism and Insulin Sensitivitymentioning

confidence: 99%

Interleukin-6 gene polymorphism and insulin sensitivity.

Fernández‐Real¹,

Broch²,

Vendrell³

et al. 2000

Diabetes

220

140

View full text Add to dashboard Cite

Type 2 diabetes and the insulin resistance syndrome have been hypothesized to constitute manifestations of an ongoing acute-phase response. We aimed to study an interleukin-6 (IL-6) gene polymorphism in relation to insulin sensitivity (I L-6 is the main cytokine involved in an acute-phase response). Subjects homozygous for the C allele at position -174 of the IL-6 gene (SfaNI genotype), associated to lower plasma IL-6 levels, showed significantly lower integrated area under the curve of serum glucose concentrations (AUC glucose ) after an oral glucose tolerance test, lower blood glycosylated hemoglobin, lower fasting insulin levels, lower total and differential white blood cell count (a putative marker of peripheral IL-6 action), and an increased insulin sensitivity index than carriers of the G allele, despite similar age and body composition. A gene dosage effect was especially remarkable for AUC g l u c o s e (6.4 vs. 9.3 vs. 9 . 7 mmol/l in C/C, C/G, and G/G individuals, respectively). The serum concentration of fully glycosylated cortisol binding globulin (another marker of IL-6 action), suggested by concanavalin A adsorption, was lower in C/C subjects than in G/G individuals (32.6 ± 2.9 vs. 37.6 ± 4.6 mg/l, P = 0.03). In summary, a polymorphism of the I L-6 gene influences the relationship among insulin sensitivity, postload glucose levels, and peripheral white blood cell count. Diabetes 49:517-520, 2000 I t has been hypothesized that type 2 diabetes and the insulin resistance syndrome are partly a manifestation of an ongoing acute-phase response (1,2). This hypothesis is based on the findings of increased blood concentrations of markers of the acute-phase response, including C-reactive protein, serum amyloid-A, -1 acid glycoprotein, sialic acid, and cortisol (1-4).Interleukin (IL)-6 is a pleiotropic cytokine involved in the regulation of the acute-phase reaction, immune responses, and hematopoiesis. Plasma IL-6 levels are elevated in type 2 diabetic patients, particularly in those with features of the insulin resistance syndrome (1,2). Although the concentrations of multiple components of the acute-phase response increase together, not all of them increase uniformly in all patients. These variations indicate that the components of the acute-phase response are individually regulated, and this may be explained in part by differences in the pattern of production of specific cytokines (5). Recently, it has been reported that a polymorphism in the 5 flanking region of the I L-6 gene alters the transcriptional response to stimuli such as endotoxin and IL-1 (6).In addition to its role in acute-phase response, IL-6 has been recently shown to be released by adipose tissue, and this release is greater in obese subjects, especially in those with a higher waist-to-hip ratio (7). Furthermore, IL-6 increases p o s t p r a n d i a l l y, in parallel to glucose and insulin levels, in the interstitial fluid of subcutaneous adipose tissue (8). This increase suggests that IL-6 might modulate adipose glucose metabolism in the...

show abstract

Blood glycoprotein levels in diabetes mellitus

Cited by 58 publications

References 20 publications

Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics.

Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics.

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X

Interleukin-6 gene polymorphism and insulin sensitivity.

Contact Info

Product

Resources

About